DeCure for Junctional epidermolysis bullosa Herlitz type
DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for junctional epidermolysis bullosa Herlitz type — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleJunctional epidermolysis bullosa Herlitz type maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for junctional epidermolysis bullosa herlitz type is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
In 2010, the field had identified at least 14 genes that cause epidermolysis bullosa, each subtype carrying its own risk of specific extracutaneous complications and premature death. Cell and animal models had been refined to test gene replacement therapy, stem cell transplantation, and treatment with injected allogeneic fibroblasts or recombinant type VII collagen, and clinical trials for each of these were being pursued in humans. No survival or response rate data were reported in that review.
A 2009 report described treating an infant with junctional epidermolysis bullosa letalis type Herlitz Pearson using cultured allogeneic keratinocyte grafts. The authors stated that effective therapy had been lacking and that any therapy improving wound healing would be beneficial. They cited previous success with cultured epidermal grafts in some epidermolysis bullosa disorders as the basis for the treatment. No numerical outcomes, survival data, or response rates were given for the infant.
A 2020 review noted that single-gene mutations disrupting structural proteins cause severe bullous disorders such as epidermolysis bullosa. It focused on model systems that recapitulate the pathological phenotype, used to decipher disease-modifying mechanisms and evaluate therapeutic possibilities aimed at reverting the genetic defect or ameliorating complications. No clinical trial results, survival figures, or response rates were reported.
What remains missing is any completed, controlled trial showing improved survival or sustained wound closure in junctional epidermolysis bullosa Herlitz type. The 2010 review listed ongoing clinical trials but provided no results. The 2009 allograft report was a single case with no quantitative follow-up. The 2020 review described models, not treatments. No money has been committed to a definitive trial for this specific subtype, and no patient stratification strategy has been validated.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Pediatrics · 2010 · 54 citations
Inherited epidermolysis bullosa: recent basic and clinical advances
AbstractPURPOSE OF REVIEW: This review highlights key findings, both clinical and basic, that have been published in the field of inherited epidermolysis bullosa within the past few years. RECENT FINDINGS: New epidermolysis bullosa phenotypes, genotypes and modes of transmission have been identified, resulting in a revised classification system. Detailed evidence-based data are now available on the risk of extracutaneous complications in each of the major epidermolysis bullosa subtypes. Studies are now underway to try to better explain the biological aggressiveness of squamous cell carcinomas arising in epidermolysis bullosa skin. Cell and animal models have been refined and used to ascertain the feasibility of gene replacement therapy, stem cell transplantation, and treatment with injected allogeneic fibroblasts or recombinant type VII collagen. As a result, clinical trials are now being pursued to test each of these in humans. SUMMARY: Epidermolysis bullosa is caused by mutations in at least 14 genes, leading to a broad spectrum of entities, each of which has its own relative risk for the development of specific extracutaneous complications and/or premature death. Intensive research, both basic and clinical, is bringing us closer to more effective treatments and possibly even a cure.
Treatment of Epidermolysis bullosa with Human Cultured Epidermal Allografts
AbstractJunctional epidermolysis bullosa letalis type Herlitz Pearson is a genetically determined, life-threatening disease. Effective therapy has been lacking to date. Therefore any therapy that improves wound healing would be beneficial for these patients. Cultured epidermal grafts are known to enhance wound epithelialization and have been used with success in some epidermolysis bullosa disorders. Encouraged by these reports, we grafted cultured allogeneic keratinocytes to an infant with a junctional epidermolysis bullosa letalis type.
Drug Discovery Today Disease Models · 2020 · 7 citations · open access
Hereditary bullous diseases: current and innovative models to study the skin blistering disease epidermolysis bullosa
AbstractAs the largest organ of the human body, our skin serves as an interface to the environment, as well as a defensive barrier against dangers therein. Its integrity is facilitated by a complex suprastructural network of proteins that tether the epidermis to the underlying dermis. Mutations in single genes that disrupt the function of these proteins lead to severe bullous disorders such as epidermolysis bullosa (EB). This short review focuses on progress in the establishment of different model systems that recapitulate multiple aspects of the pathological phenotype of EB. These models have been used to decipher disease modifying mechanisms and evaluate therapeutic possibilities aimed at reverting the genetic defect or ameliorating disease-associated complications.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
